Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy

December 20, 2010 By Bio-Medicine.Org

SAN DIEGO, Dec. 20, 2010 /PRNewswire-FirstCall/ — Amylin
Pharmaceuticals, Inc. (Nasdaq:
AMLN) today announced that it has submitted the initial
sections of a rolling submission for a Biologics License
Application (BLA) to the U.S. Food and Drug Administration (FDA)
for the use of metreleptin to treat diabetes and/or
hypertriglyceridemia (high levels of triglycerides in the
bloodstream) in patients with rare forms of lipodystrophy.
Consistent with the severity and rare nature of the disorder,
Amylin has received both orphan drug designation from FDA’s Office
of Orphan Products Development, as well as Fast Track designation
for the use of metreleptin in patients with lipodystrophy. The
focus of this marketing application is on rare inherited and
acquired forms of lipodystrophy.

In the first part of its rolling submission, the Company
submitted the nonclinical and clinical sections of the BLA. The
Company plans to submit the chemistry, manufacturing and controls
(CMC) section of the BLA by the end of 2011, which will complete
the submission.

“It is gratifying to see that, after years of research focused
on leptin as an effective therapy for lipodystrophy, we are now
closer to bringing this important and innovative medicine to
patients who are in dire need of better treatments,” said Phillip
Gorden, M.D., Director Emeritus, Senior Investigator, National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at
the National Institutes of Health (NIH). Dr. Gorden is the
principal investigator of an ongoing NIH clinical study evaluating
the long-term efficacy of metreleptin treatment in
lipodystrophy.

Lipodystrophy syndromes are characterized by abnormalities in
adipose (fat) tissue distribution with loss of subcutaneous fat,
and often manifest in childhood or adolescence. Patients with
lipodystrophy can have multiple severe metabolic abnormalities,
includin

‘/>”/>

SOURCE

Related Articles Read More >

Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech